论文部分内容阅读
目的评价依达拉奉治疗急性脑梗死的临床疗效和安全性。方法将60例急性脑梗死患者随机分为治疗组和对照组,每组30例。治疗组在对照组常规治疗基础上加用依达拉奉,比较两组的疗效。结果治疗组疗效明显优于对照组,治疗组神经功能缺损评分低于对照组,差异均有统计学意义(P<0.05)。治疗组治疗14 d后,出现转氨酶升高3例,尿素氮升高3例,均经对症治疗后降至正常。结论依达拉奉治疗急性脑梗死安全有效。
Objective To evaluate the clinical efficacy and safety of edaravone in the treatment of acute cerebral infarction. Methods Sixty patients with acute cerebral infarction were randomly divided into treatment group and control group, 30 cases in each group. The treatment group was treated with edaravone on the basis of routine treatment in the control group, and the curative effect was compared between the two groups. Results The curative effect of the treatment group was obviously better than that of the control group. The neurological deficit score of the treatment group was lower than that of the control group (P <0.05). After treatment for 14 days in treatment group, there were 3 cases of elevated aminotransferase and 3 cases of elevated urea nitrogen, which were both reduced to normal after symptomatic treatment. Conclusion Edaravone is safe and effective in the treatment of acute cerebral infarction.